Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. (Q51890664)

17 April 2018

title

Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. (English)

1 reference

17 April 2018

7

Terrence M Tumpey

1 reference

17 April 2018

Claudia Pappas

5

object named as

Claudia Pappas

1 reference

17 April 2018

author name string

Graeme E Price

1

1 reference

17 April 2018

Mark R Soboleski

2

1 reference

17 April 2018

Chia-Yun Lo

3

1 reference

17 April 2018

Julia A Misplon

4

1 reference

17 April 2018

Katherine V Houser

6

1 reference

17 April 2018

Suzanne L Epstein

8

1 reference

17 April 2018

language of work or name

English

0 references

publication date

1 September 2009

1 reference

17 April 2018

number of pages

10

1 reference

inferred from page(s)

published in

Vaccine

1 reference

17 April 2018

volume

27

1 reference

17 April 2018

issue

47

1 reference

17 April 2018

page(s)

6512-6521

1 reference

17 April 2018

Influenza vaccine: the challenge of antigenic drift.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Scientific barriers to developing vaccines against avian influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Control of influenza virus infection by immunity to conserved viral features.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Studies in experimental immunology of influenza. IV. The protective value of active immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Antibody response to the M2 protein of influenza A virus expressed in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

T-cell memory and recall responses to respiratory virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Cutting edge: Antigen is not required for the activation and maintenance of virus-specific memory CD8+ T cells in the lung airways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Measuring the diaspora for virus-specific CD8+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Beta 2-microglobulin-deficient mice demonstrate class II MHC restricted anti-viral CD4+ but not CD8+ CTL against influenza-sensitized autologous splenocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Toll-like receptor-mediated activation of neutrophils by influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

DNA vaccines: ready for prime time?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

The influenza virus variant A/FM/1/47-MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

7 January 2021

Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

7 January 2021

Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

7 January 2021

Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

7 January 2021

Immune CD4+ T cells promote the clearance of influenza virus from major histocompatibility complex class II -/- respiratory epithelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.053

7 January 2021

10.1016/J.VACCINE.2009.08.053

Identifiers

DOI

1 reference

17 April 2018

PubMed ID

19729082

1 reference

17 April 2018